prikaz prve stranice dokumenta Epidermolysis Bullosa Acquisita—Current and Emerging Treatments
  Preuzmi
PDF 1.14 MB
Znanstveni rad - Pregledni rad
Epidermolysis Bullosa Acquisita—Current and Emerging Treatments
Journal of Clinical Medicine, 12 (2023), 3; 1139. https://doi.org/10.3390/jcm12031139
Tešanović Perković, Deša; Bukvić Mokos, Zrinka; Marinović, Branka

Citirajte ovaj rad

Tešanović Perković, D., Bukvić Mokos, Z. i Marinović, B. (2023). Epidermolysis Bullosa Acquisita—Current and Emerging Treatments. Journal of Clinical Medicine, 12. (3). doi: 10.3390/jcm12031139

Tešanović Perković, Deša, et al. "Epidermolysis Bullosa Acquisita—Current and Emerging Treatments." Journal of Clinical Medicine, vol. 12, br. 3, 2023. https://doi.org/10.3390/jcm12031139

Tešanović Perković, Deša, Zrinka Bukvić Mokos i Branka Marinović. "Epidermolysis Bullosa Acquisita—Current and Emerging Treatments." Journal of Clinical Medicine 12, br. 3 (2023). https://doi.org/10.3390/jcm12031139

Tešanović Perković, D., Bukvić Mokos, Z. i Marinović, B. (2023) 'Epidermolysis Bullosa Acquisita—Current and Emerging Treatments', Journal of Clinical Medicine, 12(3). doi: 10.3390/jcm12031139

Tešanović Perković D, Bukvić Mokos Z, Marinović B. Epidermolysis Bullosa Acquisita—Current and Emerging Treatments. Journal of Clinical Medicine [Internet]. 01.02.2023. [pristupljeno 18.10.2024.];12(3). doi: 10.3390/jcm12031139

D. Tešanović Perković, Z. Bukvić Mokos i B. Marinović, "Epidermolysis Bullosa Acquisita—Current and Emerging Treatments", Journal of Clinical Medicine, vol. 12, br. 3, Veljača 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:702457. [Citirano: 18.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:702457
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Epidermolysis Bullosa Acquisita—Current and Emerging Treatments
AutorDeša Tešanović Perković
AutorZrinka Bukvić Mokos
AutorBranka Marinović
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA DERMATOVENEROLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Dermatovenerologija
Sažetak (engleski)
Epidermolysis bullosa acquisita (EBA) is a rare chronic autoimmune subepidermal blistering disease of the skin and mucous membranes, usually beginning in adulthood. EBA is induced by autoantibodies to type VII collagen, a major component of anchoring fibrils in the dermal–epidermal junction (DEJ). The binding of autoantibodies to type-VII collagen subsequently leads to the detachment of the epidermis and the formation of mucocutaneous blisters. EBA has two major clinical subtypes: the mechanobullous and inflammatory variants. The classic mechanobullous variant presentation consists of skin fragility, bullae with minimal clinical or histological inflammation, erosions in acral distribution that heal with scarring, and milia formation. The inflammatory variant is challenging to differentiate from other autoimmune bullous diseases, most commonly bullous pemphigoid (BP) but also mucous membrane pemphigoid (MMP), Brunsting–Perry pemphigoid, and linear IgA dermatosis. Due to its recalcitrance conventional treatment of epidermolysis bullosa acquisita is shown to be demanding. Here we discuss novel therapeutic strategies that have emerged and which could potentially improve the quality of life in patients with EBA.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Clinical Medicine
Brojčani podacivol. 12, br. 3, 1139
e-ISSN2077-0383
DOIhttps://doi.org/10.3390/jcm12031139
URN:NBNurn:nbn:hr:105:702457
Datum objave publikacije2023-02-01
URL dokumentahttps://www.mdpi.com/2077-0383/12/3/1139
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-01-16 08:53:12